Inhibrx Inc

Inhibrx — Investor Presentation (June 2021)

29 slides from Inhibrx's investor presentation, Jun 21, 2021

  1. Slide 1: Outcomes Focused Innovation Driven June 2021

    Outcomes Focused Innovation Driven June 2021

  2. Slide 2: Forward-looking statements

    2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol

  3. Slide 3: Inhibrx at a glance

    3 Inhibrx at a glance + Experienced leadership team + Proven innovation and execution VALIDATION FROM INDUSTRY LEADING PARTNERS All platforms and programs developed in-house with strong patent protection Inhibrx’s modular sdAb platform + Ability to precision engineer to specific target biology + Sma

  4. Slide 4: Why invest in Inhibrx?

    4 Why invest in Inhibrx? Backed by solid institutional investor base with substantial internal ownership Four differentiated clinical programs with value-creating readouts in 2H 2021/2022 KEY FINANCIAL HIGHLIGHTS* 37.8M $108.0M 41.9M Robust emerging pre-clinical pipeline Potential to reach financial

  5. Slide 5: Four differentiated clinical programs

    5 Four differentiated clinical programs INBRX-109 Tetravalent DR5 agonist + Single agent activity in chondrosarcoma and mesothelioma + Potential rapid path to approval in chondrosarcoma, registration study initiated + First combination cohorts: mesothelioma, pancreatic adenocarcinoma and Ewing sarco

  6. Slide 6: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

    INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein AAT Fc

  7. Slide 7: Alpha-1 antitrypsin deficiency (AATD)

    7 Alpha-1 antitrypsin deficiency (AATD) Disease overview ⁺ AATD is an orphan respiratory inherited disease that increases risk of developing pulmonary disease, resulting in progressive loss of lung function and decreased life expectancy ⁺ A small percentage of patients also develop liver disease Cur

  8. Slide 8: Competitive comparison of AATD therapies

    8 THERAPIES STATUS Plasma-Derived AAT Aralast Approved Glassia Prolastin-C Zemaira Inhaled AAT Phase 2 Oral Neutrophil Elastase Inhibitor Alvelestat Phase 2 Small Molecule Corrector ZF874 Phase 2 Competitive comparison Applicable to all patients THERAPIES STATUS ARO-AAT Phase 2 DCR-A1AT Phase 2 Appl

  9. Slide 9: Our solution

    9 Our solution Potential to extend the dosing range from weekly to every three weeks, while maintaining patients in the normal range of AAT exposure Engineered to maximize the functional activity of AAT, particularly in the lung Recombinant manufacturing provides lower cost of goods, unlimited suppl

  10. Slide 10: INBRX-101 Phase 1 trial design

    10 Initiated H2 2021 H1 2022 INBRX-101 Phase 1 trial design Multiple ascending dose escalation N= 18N=24 Initiated * bronchial lavage N= 6 10 mg/kg N= 6 40 mg/kg N= 6 120 mg/kg N= 6 80 mg/kg Single ascending dose escalation N= 6 40 mg/kg N= 6 80 mg/kg* N= 6 120 mg/kg* PART 1 PART 2

  11. Slide 11: INBRX-101: first human data in AAT patients

    11 INBRX-101: first human data in AAT patients Preliminary human PK data for first five AAT subjects dosed with 10 mg/kg single IV dose of INBRX-101 + Consistent with preclinical estimates + Estimated human half-life is approximately 13 days *Data from these subjects needs to be confirmed with addit

  12. Slide 12: INBRX-109 Tetravalent DR5 Agonist

    INBRX-109 Tetravalent DR5 Agonist

  13. Slide 13: Tetravalent DR5 agonist

    13 Tetravalent DR5 agonist + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells DR5: sdAd DR5: sdAdDR5: sdAd DR5: sdAd 105 kDa Fc: effector function disable

  14. Slide 14: INBRX-109 is a best-in-class DR5 agonist

    14 INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) STATUS INBRX-109 Tetravalent 105 Phase II TAS-266 Tetravalent 60 Discontinued1 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 Phase I GEN10292 Dodecavalent 150 ka (2x mAbs) Phase I IGM-8444 Decavalent3 ~950 Phase I Dulaner

  15. Slide 15: Fast to market opportunity

    15 Fast to market opportunity ~1,400 cases per year Incidence rate of ~1 in 200,000 persons per year USA Worldwide Chondrosarcoma *The figures on this slide represent market research estimates. No approved therapeutic for the treatment of chondrosarcoma Therapeutic IPI-926 (HH) Control arm Placebo S

  16. Slide 16: INBRX-109 preliminary Phase 1 data in chondrosarcoma

    16 Best Response 3mo 4mo 6mo 9mo 12mo SD (-20%) 62wks ► SD (-7%) 62wks PD SD (-11%) 54wks ► PR (-60%) PD SD (-13%) PD SD (+4%) ► PR (-32%) PD SD (-4%) ** SD (+5%) PD SD (+3%) * SD (-3%) * SD (-4%) * SD (+6%) PD SD (+7%) PD PD PD PD PD Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

  17. Slide 17: INBRX-109 Phase 2 registration-enabling study design

    17 Endpoints Primary: Progression free survival Secondary: Overall survival, overall response rate, duration of response, disease control rate, quality of life INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization Conventional chondrosarcoma, grade 2 and 3, unresectabl

  18. Slide 18: Preliminary Phase 1 data in mesothelioma combination

    18 Best Response 3mo 4mo 6mo 9mo SD (-24%) * SD (-17%) SD (-12%) PR (-100%) SD (-22%) SD (-20%) sd (-12%) SD (-5%) SD (-2%) SD (+9%) SD (+13%) SD (+16%) SD (+1%) * PD PD PD PD (+25%) PD (+33%) PD (+33%) Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 3

  19. Slide 19: INBRX-109 on the horizon

    19 Planned Ongoing FUTURE POTENTIAL OPPORTUNITIES Solid tumors + IAP antagonists Hematologic tumors + Bcl-2 inhibitors NSCLC + various combo agents Gastric and colon cancer + various combo agents Additional sarcoma indications INBRX-109 on the horizon Combination studies Pancreatic adenocarcinoma 2n

  20. Slide 20: INBRX-106 Hexavalent OX40 Agonist

    INBRX-106 Hexavalent OX40 Agonist

  21. Slide 21: Hexavalent OX40 agonist

    21 Hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T- cells: + Provides co-stimulation to activated T-cells + Reverses regulatory T-cell induced immune suppression + Enhances T-cell functionality + Additional benefit in combination with PD-1 blockade T T T T T T T T T OX40: sd

  22. Slide 22: INBRX-106 is a best-in-class OX40 agonist

    22 INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hex- IgG1 N Ph 1 (2019) MOXR-0916 Bi- IgG1 Y Discontinued GSK-3174998 Ph 1 (MM, 2019) BMS-986178 Ph 1 (2016) INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Disc

  23. Slide 23: INBRX-106 Phase 1 trial design

    23 INBRX-106 Phase 1 trial design No pre-screening, all-comers Dose optimization study PlannedInitiatedInitiatedCompleteSingle agent dose escalation Dose escalation with Keytruda™ Single agent dose expansion N=80N= 24 N= 13N=20 N=20 PD-L1+NSCLC N=20 PD-L1+NSCLC N=20 PD-L1+Basket N=20 PD-L1+NSCLC, CP

  24. Slide 24: INBRX-105 PD-L1 x 4-1BB Multispecific

    INBRX-105 PD-L1 x 4-1BB Multispecific

  25. Slide 25: PD-L1 x 4-1BB multispecific

    25 PD-L1 x 4-1BB multispecific + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune cells, 4-1BB signaling promotes prolonged T- cell survival memory formation + Constitutive 4-1BB agonism has achieved anti- tumor respo

  26. Slide 26: INBRX-105 is a best-in-class 4-1BB agonist

    26 INBRX-105 is a best-in-class 4-1BB agonist CANDIDATE FORMAT 4-1BBL BLOCKING STATUS INBRX-105 Bivalent/Bivalent No Phase I Gen-1064 Monovalent/Monovalent n/a Phase II MCLA-145 Monovalent/Monovalent Yes Phase I FS222 Bivalent/Bivalent n/a Phase I PRS-343 Bivalent/Bivalent No Phase I ND021 Monovalen

  27. Slide 27: INBRX-105 Phase 1 trial design

    27 PlannedInitiatedInitiatedComplete INBRX-105 Phase 1 trial design Single agent: PD-L1+ Basket Single agent dose escalation Single agent dose expansion N=80N= 32 N= 12N=32 No pre-screening, all-comers + 8/18 (44%) at dose levels ≥ 0.1 mg/kg achieved stable disease + Patients were not pre-screened f

  28. Slide 28: Near term expected clinical milestones

    28 Near term expected clinical milestones H2 2021 H1 2022 H2 2022 INBRX-109 (OX40) / Keytruda dose escalation data (OX40) / Keytruda dose expansion cohort data (AAT) Initial Phase 1 data (AAT) Additional Phase 1 data (DR5) Initiation of chondrosarcoma registration-enabling trial (PD-L1 x 41BB) Keytr

  29. Slide 29: Inhibrx contact details

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com

Inhibrx — Investor Presentation (June 2021) on 6ix